Drug Profile
Oxybutynin controlled release vaginal - Teva Pharmaceutical Industries
Alternative Names: DR-3001; Enhance UI; Oxybutynin transvaginal ring (TVR) - TevaLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Duramed Pharmaceuticals Inc
- Developer Teva Pharmaceutical Industries
- Class Alkynes; Antispasmodics; Carbocyclic acids; Cyclohexanes; Diethylamines; Esters; Mandelic acids; Skin disorder therapies; Small molecules
- Mechanism of Action Cholinergic receptor antagonists; Muscarinic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Overactive bladder
Most Recent Events
- 31 Dec 2013 Discontinued - Phase-III for Overactive bladder in USA and Canada (Vaginal)
- 07 May 2012 Efficacy data from a phase II trial in Overactive bladder presented at the American Congress of Obstetricians and Gynecologists Annual Clinical Meeting (ACOG-2012)
- 31 Jul 2010 Duramed completes a phase III safety extension trial (NCT00782769) in Overactive bladder in the US